We tested the hypothesis that pulmonary surfactant-associated lectins--surfactant proteins A and D (SP-A, and -D)--contribute to initial protective mechanisms against influenza A viruses (IAVs). SP-D potently inhibited hemagglutination activity of several strains of IAV as well as causing viral aggregation. SP-D enhanced neutrophil binding of IAV and neutrophil respiratory burst responses to the virus. Neutrophil dysfunction resulting from IAV exposure was diminished when the virus was pre-incubated with SP-D. Each of these effects was mediated by the calcium-dependent carbohydrate-binding property of SP-D. Native SP-D preparations of both human and rat origin, as well as recombinant rat SP-D, had similar activity. SP-A also inhibited IAV hemagglutination activity. We have previously reported that related mammalian serum lectins (mannose-binding lectin [MBL] and conglutinin) have similar effects. SP-D was at least 10-fold more potent at causing hemagglutination inhibition than were SP-A or MBL. SP-D was shown to contribute to potent anti-IAV activity of human bronchoalveolar lavage fluid. These results suggest that SP-D--alone, and in conjunction with SP-A and phagocytic cells--constitutes an important component of the natural immune response to IAV infection within the respiratory tract. 
Introduction
Surfactant protein D (SP-D)' is a member of the collectin subgroup of the mammalian C-type lectin superfamily, which includes another surfactant protein, surfactant protein A (SP-A), and at least two serum proteins, mannose-binding lectin (MBL), and conglutinin (1, 2) . Each of these lectins has been shown to bind to a variety of microorganisms, and may have a role in host defense responses, both through inhibiting infecti-vity of various organisms directly, and by enhancing phagocyte activation (3) (4) (5) (6) (7) (8) (9) . The evidence for this is strongest with MBL, in that low levels of this protein have been associated with a syndrome of increased susceptibility to infection during infancy (2) . We have previously reported that MBL and conglutinin inhibit the infectivity and hemagglutination (HA) activity of influenza A viruses (IAV) by binding to carbohydrates present on the viral HA molecule (10, 11) . These lectins also act as opsonins, promoting neutrophil activation in response to IAV. The strong structural relationship of these lectins with SP-D (e.g., 66% amino acid sequence identity of human SP-D with conglutinin) (12, 13) , and the fact that SP-D accumulates in the lower respiratory tract at sites suitable to interact with IAV in vivo (14) , prompted us to examine the activity of SP-D against IAV in vitro.
The collectins naturally occur as multimeric structures resembling Clq in having collagenous domains which tether multiple globular carbohydrate recognition domains (2, 15) . SP-D is produced by alveolar type II pneumocytes and by Clara cells (nonciliated bronchiolar cells) ( 14) . It has been shown to be a major E. coli binding protein in bronchoalveolar lavage fluid, and can bind to and aggregate a range of bacteria via its calciumdependent, carbohydrate binding activity (8) . Rat and human SP-D have very similar sugar binding specificity and have similar interactions with bacteria (8, 12) . In addition, SP-D has been shown to bind to alveolar macrophages ( 16) and to stimulate a chemiluminescence response in these cells (9).
We here report that SP-D of human and rat origin share with MBL and conglutinin the ability to potently inhibit HA activity of a variety of strains of IAV, and to enhance neutrophil activation by IAV.
Methods
Reagents. Formylmethionylleucylphenylalanine (FMLP), cytochalasin B, horseradish peroxidase-Type II, scopoletin, superoxide dismutase (SOD), cytochrome-C, maltose, Ficoll, dextran, sodium citrate, maltosyl-agarose, and citric acid were purchased from Sigma Chemical Co. (St. Louis, MO) and Hypaque was obtained from Winthrop Pharmaceuticals (Des Plaines, IL). Dulbecco's phosphate-buffered saline with or without Ca2+ or Mg2+ was purchased from Flow Labs (McClean, VA). Tris buffered saline contained either 2 mM Ca2" or 10 mM EDTA, as indicated.
SP-D preparation. Native rat SP-D was isolated from the 10,000 g supernatant of bronchoalveolar lavage from silicotic rats (17) . Human SP-D was isolated from the supernatant of lavage obtained from patients with human alveolar proteinosis ( 18) . In higher aggregates. The procedures for purification of these proteins have been previously published in greater detail (17, 18) . As established in those publications these SP-D preparations were free of contamination with other proteins including SP-A based on SDS-PAGE and immunoblotting analysis.
Recombinant rat SP-D was derived from a full length clone of rat SP-D cDNA stably expressed in CHO KI cells. The protein comigrated with native rat SP-D on SDS-PAGE under reducing and nonreducing conditions, showed the expected shift in apparent molecular mass after incubation with endoglycosidase F, bound efficiently to maltosyl-agarose, and eluted at the expected position on nondenaturing gel filtration chromatography. A more detailed description of the expression and purification of this protein is in preparation.
Human surfactant protein A (SP-A) was graciously provided by Drs. Virginia Shepherd and Zissis Chroneos (Vanderbilt University, Nashville, TN). The SP-A was purified from alveolar proteinosis patients as described (19) and was shown to be at least 95% pure by SDS-PAGE analysis and by '"I labeling followed by SDS-PAGE and autoradiography. Fig. 1 depicts the appearance of the SP-A used in these studies on SDS-PAGE. An additional lane showing the migration of native human SP-D is included for comparison. Note that the SP-A appears as a broad band of 26-36 kD as well as another band of -62 kD. This is the typical appearance of purified SP-A derived from alveolar proteinosis patients when analyzed by SDS-PAGE under reducing conditions (19) . Previous studies have demonstrated with amino acid sequencing and other methods that these bands represent monomeric and dimeric forms of SP-A (20) .
Bronchoalveolar lavage (BAL) fluids were obtained from healthy volunteer donors with informed consent as approved by the Boston University School of Medicine Institutional Review Board for Human Research. Between 150 and 200 ml of normal saline was instilled for the lavage. Fluids retrieved from this procedure were subjected to an initial low speed centrifugation ( 150 g) to remove cells and other large particulates. Further processing of the fluid was carried out as described below.
The ELISA assay to measure SP-D levels employed native human SP-D and the immunoglobulin fraction of a well-characterized rabbit anti-SP-D antiserum (8) to establish a standard curve. The assay detected concentrations between 5 and 250 ng/ml of human SP-D in a linear manner. Purified SP-D or BAL fluids were coated overnight on microtiter wells, then washed three times with PBS-Tween followed by blocking of nonspecific binding sites with 0.25% BSA in PBS-Tween. After further washing, the wells were incubated for 2 h with a 1:1,000 dilution of the anti-SP-D immunoglobulin preparation. After washing, a 1:1,000 dilution of goat anti-rabbit polyclonal IgG conjugated to horseradish peroxidase (HRP; Sigma Chemical Co.) was then added for 2 h, followed by washing and development using TMB peroxidase substrate (Bio Rad Laboratories). The reaction was stopped using H2SO4, and absorbance read at 450 nm. All samples were run in duplicate. Protein assays were performed using BCA protein assay according to manufacturer's specifications (Sigma Chemical Co.).
Binding of purified SP-D, or of SP-D present in BAL fluid, to IAV was assessed by a dot blot assay. Twofold dilutions of purified IAV (Mem71H-BelN strain) were blotted on to nitrocellulose paper (Micron Separations Inc., Westboro, MA) and allowed to air dry. The virus dilution buffer was PBS containing 200 ,g/ml of bovine serum albumin (BSA). Blots containing the dilution buffer and/or secondary antibody alone were included. The dried strips were then immersed in 5% nonfat dry milk in TBS for 1 h at room temperature. After washing twice in TBS containing 0.3% Tween, the strips were incubated with either purified SP-D (200 ng/ml) or BAL samples for 18 h at 40C. After washing again twice in TBS containing 0.3% Tween, the strips were incubated in TBS with 5% milk containing a 1:500 dilution of rabbit anti-SP-D IgG for 1 h at room temperature. After further washing, the strips were incubated with TBS containing a 1:1,000 dilution of goat anti-rabbit IgG conjugated to HRP for 1 h at 37TC. Peroxidase activity was detected using a chemiluminescence reaction (ECL System; Amersham, U.K.).
Virus preparation. Virus stocks were grown in the chorioallantoic fluid of 10-d-old embryonated hen's eggs, and purified on a discontinuous sucrose density gradient as previously described (21, 22) . Virus stocks were suspended in Dulbecco's modified phosphate-buffered saline (PBS), aliquoted and stored at -70'C until used. Potency of each virus stock was measured by hemagglutination assay, and titers of 1:8,000 through 1:32,000 (as indicated) hemagglutination units (HAU) were measured after samples were thawed from storage at -70°C. Hem (24, 25) .
Addition of SP-D to virus-free buffer containing 2 mM Ca2" did not cause any decrease in light transmission.
Measurement ofneutrophil activation. Neutrophils from healthy volunteer donors were isolated to > 95% purity as previously described using dextran sedimentation, followed by a Ficoll-Hypaque gradient centrifugation for removal of mononuclear cells, and hypotonic lysis to eliminate contaminating erythrocytes (21) . Cell viability was > 98% as determined by trypan blue staining, and cells were used within five hours of isolation. H202 production was measured by the oxidation of scopoletin, and°2 assessed by the continuous monitoring of the SOD inhibitable reduction of cytochrome C as previously detailed (26) . Neutrophil deactivation was assessed by first incubating cells with IAV for 10 min., followed by measurement of°2 production in response to FMLP (10, 21) .
Measurement of influenza virus binding to neutrophils. Viral binding to neutrophils was measured by preparing FITC-labeled virus and incubating this preparation with neutrophils, followed by evaluation of cell associated fluorescence using a flow cytometer. FITC stock was prepared at 1 mg/ml in 1 M sodium carbonate, pH 9.6. The FITC labeled virus was prepared by incubating concentrated virus stocks with FTIC (10:1 mixture by volume of virus in PBS with FITC stock) for 1 h, followed by dialysis of the mixture for 18 h against PBS. For fluorescence measurements, concentrated FITC-labeled virus was incubated for 30 min at 37°C with control buffer or various amounts of SP-D, followed by addition of 10-pl aliquots of these samples to neutrophils (106 cells in 100 Isl TBS containing either 2 mM Ca2+ or 10 mM EDTA, as indicated). In some samples SP-D was pre-incubated with maltose (167 mM) before mixing SP-D with virus. After allowing virus and neutrophils to interact for 15 min at 4°C, the neutrophils were washed, resuspended in virus-free PBS and fixed with 2% paraformaldehyde. Cell associated fluorescence was measured on a Becton-Dickinson FACS Scan 2 and analyzed using the Lysis II program.
Results
Effect of incubation with SP-Ds on hemagglutination activity of IAV. As presented in Table I , native rat and human SP-D inhibited HA activity of all H3 strains of IAV tested in a Ca2+-dependent manner. Recombinant rat SP-D had similar HA inhibitory effects. The Brazil 78 strain of 1AV which is of the HI subtype was also inhibited by the SP-Ds. If SP-Ds were pre-incubated with maltose they lost the ability to inhibit IAV HA activity. In contrast, pre-incubation with 2 160 mM of either galactose or N-acetyl glucosamine did not reduce HA inhibitory effects of SP-D (data not shown). These results indicate that HA inhibition by SP-D was mediated by its Ca2+-dependent, lectin activity, and are compatible with the known carbohydrate-binding specificities of SP-D. SP-D had much less activity against the PR-8 HINI strain of IAV (see Table I ). The PR-8 strain of IAV differs from H3 strains in that it lacks high mannose oligosaccharide attachments on its HA and has no carbohydrate attachment near the sialic acid binding site (27, 28) .
Another approach was taken to characterizing the HA inhibitory effects of the SP-Ds that involved pre-incubation of much more concentrated preparations of IAV with escalating doses of the SP-Ds, followed by measurement of HA activity. As Table I ). In addition, the concentrations of maltose used in these experiments do not inhibit HA activity (see Table I ). HA titers at all concentrations tested, including 1.7 /Ag/ml, but again only in TBS with 2 mM Ca2+ without maltose.
ments testing the effects of SP-D on IAV binding to neutrophils are depicted in Fig. 4 . A concentrated stock of FITC-labeled Bangkok 79 IAV was pre-incubated with various concentrations of SP-Ds as described in Fig. 2 , followed by addition of aliquots of these preparations to a suspension of neutrophils. As assessed by mean cell fluorescence, native rat SP-D caused a marked increase in viral binding to the neutrophil, which was most pronounced where virus stock had been pre-incubated with 7 pig/ml of SP-D. Recombinant rat SP-D (5.9 ,jg/ml) also enhanced IAV binding when tested in a similar manner in three experiments (data not shown). Human SP-D caused optimal binding enhancement at 3.5 Mg/ml, and significantly increased binding at 1.7 psg/ml.
The effects of native rat and human SP-Ds on viral binding to neutrophils were abrogated if the SP-D was pre-incubated with maltose prior to incubation with IAV, or if the experiments were carried out in EDTA (Fig. 4) . EDTA had no Ca2", except where EDTA is indicated, in which case the assay was performed in TBS with 10 mM EDTA. Except for assays in EDTA, SP-D (which is stored in TBS containing 10 mM EDTA) was recalcified immediately before assay. Results represent mean±SEM of three similar experiments for the 366 ng/ ml dose of rat SP-D, and the 125 and 250 ng/ml doses of human SP-D. The decline in light transmission 5 min. after addition of SP-D was significant (P : 0.01 ) for these samples. The remaining experiments are representative of two performed. In tracings designated " EDTA 586 and 400 ng/ml of rat and human SP-D, respectively, were added at 300 s. In EDTA experiments no perceptible change in light transmission occurred upon addition of SP-Ds. In the tracing designated "Maltose," 586 ng/ml of rat SP-D (in TBS with Ca2+) which had been pre-incubated with 167 mM maltose was added at 300 s. No perceptible response to the SP-D occurred in this setting. Human SP-D Concentratlon(ug/ml) were used in these experiments as those described in Fig. 1 104±31 ng/ml. Hence, as previously reported (18, 31 ) the majority of SP-D is soluble and not surfactant-associated. Based on our findings using purified SP-Ds, the concentrations of SP-D present in these BAL samples would be sufficient to show functional activity vs. IAV. SP-D present in whole BAL bound to IAV as assessed using a dot blot assay (Fig. 8, Panel A) . Sufficient SP-D was also present in the 10,000 g supernatant of BAL to show comparable binding to IAV (Fig. 8, Panel B) . No binding of SP-D in BAL to control buffer alone or to BSA was detected. Nonspecific binding of immunoglobulins to the virus was also ruled out. alone. No O2 was generated during incubation of the neutrophils with IAV alone, or IAV complexed with SP-D (data not shown). Addition of 440 ng/ml (final concentration) of native rat SP-D alone to neutrophils followed after 10 min by addition of FMLP led to a slight enhancement of the neutrophil°2 response to FMLP (9±2% increase; n = 3; P c 0.01) as compared to control neutrophils. When FITC-labeled Bangkok 79 IAV was pre-incubated with this concentration of rat SP-D followed by addition of neutrophils to this mixture, the O2 response to FMLP was increased by 31±4% as compared with cells treated with IAV alone (n = 4; P < 0.05). The SP-Dopsonized IAV preparation also showed significantly enhanced binding to neutrophils (37±7%; n = 4; P 5 0.005) compared to unopsonized IAV.
HA inhibitory activity of human bronchoalveolar lavage (BAL) fluids. An ELISA assay was developed to measure SP-D levels in BAL fluids obtained from healthy volunteer donors. We first measured the levels of SP-D present in BAL which had only been subjected to a 150 g centrifugation (hence still containing surfactant). The mean SP-D concentration in BAL fluid samples obtained from five donors was 139±29 ng/ml. The total protein concentration for these BAL fluid samples was 34±10 jig/ml. SP-D represented 0.5±0.1% of the total protein in these samples. The anti-SP-D immunoglobulin preparation at the dilution used in this assay had no significant reactivity with purified human SP-A. These SP-D values are similar to those that have previously been reported (18) . We then subjected the BAL samples to a 10,000 g centrifugation. The vast majority of SP-A (99%) is insoluble and is concentrated in the surfactant pellet by this maneuver (31) bind to BSA (200 ,g/ml) alone or buffer alone. Purified SP-D also did not bind in this setting (data not shown). In row I the supernatant of BAL which had been subjected to a 10,000 g centrifugation (to remove surfactant and SP-A) was used (denoted as BAL [pre-adsorption] significantly (although incompletely) reduced the HA inhibitory activity of the BAL. SP-A has been reported to have anti-IAV activity (32). However, SP-A on its own is unlikely to have been responsible for the majority of HA inhibiting activity in BAL (Table H) . The average concentration of SP-A present in the 150 g supernatant of BAL fluid has been determined to be approximately 0.83 Ig/ml (33) . Using purified, solubilized SP-A, substantially higher concentrations of SP-A were required to achieve a degree of HA inhibition comparable to that obtained using the 150 g supernatant of BAL (Table II) . The HA inhibiting effects of SP-A were not statistically significantly reduced by addition of maltose to the assay (while, as expected, maltose completely prevented SP-D from exerting HA inhibiting effects). Furthermore, the 10,000 g supernatant of BAL (which contains minimal amounts of SP-A) retained substantial HA inhibitory activity. Note that SP-D was more than tenfold as potent as SP-A at inhibiting HA activity, and that SP-D exhibited additive HAinhibiting effects when added simultaneously with SP-A (Table H).
To confirm that SP-D contributes to the overall HA inhibitory activity of BAL, we adsorbed the 10,000 g supernatant of BAL with maltosyl-agarose. Pre-and post-adsorption samples were adjusted to have the same total protein concentration by use of Centricon microconcentrators (Amicon Co., Beverly, . Inhibition of IAV HA activity caused by BAL fluid before and after adsorption by maltosyl-agarose. The 10,000 g BAL supernatant pre-and post-adsorption by maltosyl-agarose (prepared as described in Fig. 8 Table II ), with the former acting principally at the surfactant interface, and the latter in the fluid phase of the airways.
The serum proteins MBL and conglutinin, which bear significant homology to SP-D, also have similar ability to inhibit HA activity and enhance neutrophil responses upon exposure to the virus (10, 11) . Of note, SP-D exceeds these serum lectins in potency in these assays. Concentrations of MBL are required to achieve similar HA inhibition, or respiratory burst enhancement exceed those of SP-D by 10-fold or more. While the HA inhibitory potency of conglutinin is similar to that of SP-D, to achieve optimal IAV aggregation or neutrophil respiratory burst enhancement 1.5 yig/ml ( 
